Navigation Links
Cell Therapeutics, Inc. Announces $6.5 Million Offering
Date:11/30/2007

SEATTLE, Nov. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has entered into agreements to sell approximately $6.5 million of its 7% Convertible Preferred Stock and warrants in a registered offering to several institutional investors, including certain of its existing securities holders. CTI will sell Series D convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of Series D convertible preferred stock. The Preferred Stock will be convertible into shares of common stock beginning on or about December 3, 2007, at a conversion price of $2.6125 per share. Purchasers will also receive warrants to purchase common stock in an amount equal to 50% of their total investment amount divided by $2.6125, which warrants will have an exercise price of $2.55 per share, which is equal to the closing bid price of the Company's common stock as reported on the NASDAQ Global Market on November 29, 2007. The warrants will not be exercisable until six months following the closing. The Company intends to use the proceeds of the offering towards the closing of its purchase of ZEVALIN(R) from Biogen Idec Inc. and for general corporate purposes.

The offering is expected to close on December 3, 2007, subject to certain closing conditions.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the offering.

<
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ... the new Global Communications Director for InHealth Media. Mr. Spector comes with ... last 16 years doing on-air television, producing shows, on air-radio and media relations. ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Executive Vice President Jeff Fernandez will lead the expansion of global ... of cosmeceutical and skin care experience having spent the last 25 years working ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris Bustamante ... Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado ... its reach and impact through innovative technologies and strategies. , “I am very proud ...
(Date:8/29/2015)... ... 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of ... will present an educational program titled “Asbestos and Your Health.” , The two and ... open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2
... Louisville Health Sciences Center faculty and students made an ... four regions of Kentucky served by UofL Area Health ... donated services valued at $5,606,599 while their students spent ... in the four regions. These regions encompass 56 counties ...
... HealthDay Reporter , WEDNESDAY, Jan. 11 (HealthDay News) -- Americans ... life expectancy going from 78.6 years in 2009 to 78.7 ... a percent between 2009 and 2010, and hit the lowest ... the latest set of data from the U.S. Centers for ...
... , WEDNESDAY, Jan. 11 (HealthDay News) -- The first major gene ... been identified by scientists. Men who inherit the mutation in ... of developing prostate cancer, according to the study in the Jan. ... The HOXB13 gene plays an important role in the development ...
... WEDNESDAY, Jan. 11 (HealthDay News) -- A new type of ... to help re-educate rogue immune system cells, which allows cells ... The treatment, which combines a patient,s immune system cells with ... people with long-standing diabetes who were believed to have no ...
... News) -- A small study that offers new insight into ... effective treatments for people with drinking problems. Researchers used ... alcohol in the brains of 13 heavy drinkers and a ... In all of the participants, drinking alcohol triggered the ...
... have discovered that a subtype of leukemia characterized by ... distinctly different from a seemingly similar leukemia associated with ... Jude Children,s Research Hospital Washington University Pediatric Cancer ... treating patients with this more aggressive cancer. ...
Cached Medicine News:Health News:UofL centers have economic impact in excess of $5.7 million 2Health News:UofL centers have economic impact in excess of $5.7 million 3Health News:Americans Living Longer, Report Finds 2Health News:Americans Living Longer, Report Finds 3Health News:Scientists Identify Inherited Prostate Cancer Gene 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 3Health News:Alcohol Targets Brain 'Reward Centers' in Heavy Drinkers 2Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 2Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 3Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 4
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 2015 Perrigo Company plc ("Perrigo") (NYSE: ... ("Mylan") (NASDAQ: MYL ) shareholder vote regarding its ... views of Mylan,s offer to Perrigo shareholders have always ... Board,s careful reflection of the value available to Perrigo ... that Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: